| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The molecular targets include dopamine D2 and serotonin 5-HT2A receptors (antagonist), 5-HT7 (antagonist), and 5-HT1A (partial agonist); lurasidone binds D2 and 5-HT2A with high affinity (Ki in the low nanomolar range), and its 5-HT7 antagonism and 5-HT1A partial agonism may contribute to its antidepressant and pro-cognitive effects.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, lurasidone-d8 competes with radioligands for D2, 5-HT2A, 5-HT7, and 5-HT1A receptors with high affinity, antagonizes dopamine- and serotonin-induced signaling in transfected cells, and shows partial agonist activity at 5-HT1A receptors; the deuterated form retains multi-receptor activity while enabling LC-MS/MS quantification. |
| ln Vivo |
In vivo, oral lurasidone-d8 produces antipsychotic-like effects in rodent models (conditioned avoidance, locomotor activity), reduces phencyclidine-induced cognitive deficits, and shows antidepressant-like activity in forced swim tests; the labeled form is used to quantify plasma and brain concentrations and to relate multi-receptor occupancy to behavioral effects.
|
| Enzyme Assay |
Noncellular binding assays incubate membrane homogenates expressing recombinant D2, 5-HT2A, 5-HT7, or 5-HT1A receptors with selective radioligands and increasing concentrations of lurasidone-d8; Ki values are calculated from displacement curves, and selectivity across the receptor panel is determined.
|
| Cell Assay |
Cellular functional assays use CHO or HEK293 cells expressing D2, 5-HT2A, or 5-HT1A receptors and measure lurasidone-d8–mediated antagonism of agonist-induced calcium mobilization or cAMP modulation, with 5-HT1A partial agonist activity assessed by [35S]GTPγS binding.
|
| Animal Protocol |
Animal protocols administer lurasidone-d8 orally or intraperitoneally to rats or mice at doses of 1–30 mg/kg; antipsychotic-like behavior, cognitive function, and antidepressant-like effects are measured, and plasma and brain concentrations are quantified by LC-MS/MS to relate multi-receptor occupancy to behavioral outcomes.
|
| References |
|
| Molecular Formula |
C28H36N4O2S
|
|---|---|
| Molecular Weight |
500.725338935852
|
| Exact Mass |
500.306
|
| CAS # |
1132654-54-6
|
| Related CAS # |
Lurasidone;367514-87-2
|
| PubChem CID |
118988637
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
623.4±55.0 °C at 760 mmHg
|
| Melting Point |
259-261°C (dec.)
|
| Flash Point |
330.8±31.5 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.637
|
| LogP |
4.52
|
| tPSA |
85
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
35
|
| Complexity |
804
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
S1C2C=CC=CC=2C(=N1)N1C([2H])([2H])C([2H])([2H])N(C([2H])([2H])C1([2H])[2H])C[C@@H]1CCCC[C@H]1CN1C([C@H]2[C@@H](C1=O)[C@@H]1CC[C@H]2C1)=O
|
| InChi Key |
PQXKDMSYBGKCJA-KBFPQGGWSA-N
|
| InChi Code |
InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1/i11D2,12D2,13D2,14D2
|
| Chemical Name |
(1R,2S,6R,7S)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)-2,2,3,3,5,5,6,6-octadeuteriopiperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9971 mL | 9.9854 mL | 19.9708 mL | |
| 5 mM | 0.3994 mL | 1.9971 mL | 3.9942 mL | |
| 10 mM | 0.1997 mL | 0.9985 mL | 1.9971 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.